Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Zynerba Pharmaceuticals stock | $5.22
Learn how to easily invest in Zynerba Pharmaceuticals stock.
Zynerba Pharmaceuticals, Inc is a drug manufacturers-specialty & generic business based in the US. Zynerba Pharmaceuticals shares (ZYNE) are listed on the NASDAQ and all prices are listed in US Dollars. Zynerba Pharmaceuticals employs 26 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Zynerba Pharmaceuticals
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – ZYNE – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Zynerba Pharmaceuticals stock price (NASDAQ: ZYNE)Use our graph to track the performance of ZYNE stocks over time.
Zynerba Pharmaceuticals shares at a glance
|Latest market close||$5.22|
|52-week range||$3.15 - $9.00|
|50-day moving average||$5.14|
|200-day moving average||$4.74|
|Wall St. target price||$7.63|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.89|
Buy Zynerba Pharmaceuticals shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Zynerba Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Zynerba Pharmaceuticals price performance over time
|1 week (2021-07-21)||N/A|
|1 month (2021-07-01)||-2.43%|
|3 months (2021-04-30)||18.37%|
|6 months (2021-01-28)||N/A|
|1 year (2020-07-28)||N/A|
|2 years (2019-07-28)||N/A|
|3 years (2018-07-28)||N/A|
|5 years (2016-07-28)||N/A|
Zynerba Pharmaceuticals financials
|Gross profit TTM||$0|
|Return on assets TTM||-33.16%|
|Return on equity TTM||-58.02%|
|Market capitalisation||$181.9 million|
TTM: trailing 12 months
Shorting Zynerba Pharmaceuticals shares
There are currently 2.1 million Zynerba Pharmaceuticals shares held short by investors – that's known as Zynerba Pharmaceuticals's "short interest". This figure is 7.5% down from 2.2 million last month.
There are a few different ways that this level of interest in shorting Zynerba Pharmaceuticals shares can be evaluated.
Zynerba Pharmaceuticals's "short interest ratio" (SIR)
Zynerba Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Zynerba Pharmaceuticals shares currently shorted divided by the average quantity of Zynerba Pharmaceuticals shares traded daily (recently around 800039.92248062). Zynerba Pharmaceuticals's SIR currently stands at 2.58. In other words for every 100,000 Zynerba Pharmaceuticals shares traded daily on the market, roughly 2580 shares are currently held short.
However Zynerba Pharmaceuticals's short interest can also be evaluated against the total number of Zynerba Pharmaceuticals shares, or, against the total number of tradable Zynerba Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Zynerba Pharmaceuticals's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Zynerba Pharmaceuticals shares in existence, roughly 50 shares are currently held short) or 0.0527% of the tradable shares (for every 100,000 tradable Zynerba Pharmaceuticals shares, roughly 53 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Zynerba Pharmaceuticals.
Find out more about how you can short Zynerba Pharmaceuticals stock.
Zynerba Pharmaceuticals share dividends
We're not expecting Zynerba Pharmaceuticals to pay a dividend over the next 12 months.
Zynerba Pharmaceuticals share price volatility
Over the last 12 months, Zynerba Pharmaceuticals's shares have ranged in value from as little as $3.15 up to $9. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Zynerba Pharmaceuticals's is 2.4755. This would suggest that Zynerba Pharmaceuticals's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Zynerba Pharmaceuticals overview
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. It focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It improves the lives of patients and their families living with severe, chronic health conditions, including Fragile X syndrome, autism spectrum disorder, 22q11. 2 deletion syndrome, and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc.
Stocks similar to Zynerba Pharmaceuticals
Zynerba Pharmaceuticals in the news
Rising High: Tilray reports Q4 earnings as GrowGeneration to acquire HGS Hydro
Rising High: Tilray reports Q4 earnings as GrowGeneration to acquire HGS Hydro
Marijuana Vs. Mushroom Psychedelic Drug Stocks
Frequently asked questionsWhat percentage of Zynerba Pharmaceuticals is owned by insiders or institutions?
Currently 2.604% of Zynerba Pharmaceuticals shares are held by insiders and 29.749% by institutions. How many people work for Zynerba Pharmaceuticals?
Latest data suggests 26 work at Zynerba Pharmaceuticals. When does the fiscal year end for Zynerba Pharmaceuticals?
Zynerba Pharmaceuticals's fiscal year ends in December. Where is Zynerba Pharmaceuticals based?
Zynerba Pharmaceuticals's address is: 80 West Lancaster Avenue, Devon, PA, United States, 19333 What is Zynerba Pharmaceuticals's ISIN number?
Zynerba Pharmaceuticals's international securities identification number is: US98986X1090 What is Zynerba Pharmaceuticals's CUSIP number?
Zynerba Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 98986X109
More guides on Finder
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
How to buy DoubleDown Interactive (DDI) stock when it goes public
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
How to buy Omniq Corp (OMQS) stock when it goes public
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
How to buy Mechanical Technology (MKTYP) stock when it goes public
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
Ask an Expert